Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours

Frequency, localization, and types of gastrointestinal stromal tumor-associated neoplasia

BACKGROUND

In recent years, increasing evidence of second neoplasms associated with gastrointestinal stromal tumors (GIST) has been found. Numerous case reports, mostly retrospective studies and a few reviews, have been published. To our knowledge, however, no systematic review or meta-analysis of the existing data has been performed so far.

AIM

To prepare a compilation, as complete as possible, of all reported second tumor entities that have been described in association with GIST and to systematically analyze the published studies with regard to frequency, localization, and types of GIST-associated neoplasms.

METHODS

The MEDLINE and EBSCO databases were searched for a combination of the keywords GIST/secondary, synchronous, coincident/tumor, neoplasm, and relevant publications were selected by two independent authors.

RESULTS

Initially, 3042 publications were found. After deletion of duplicates, 1631 remained, and 130 papers were selected; 22 of these were original studies with a minimum of 20 patients, and 108 were case reports. In the 22 selected studies, comprising a total number of 12050 patients, an overall rate of GIST-associated neoplasias of 20% could be calculated. Most second neoplasias were found in the gastrointestinal tract (32%) and in the male and female urogenital tract (30%). The specific risk scores of GISTs associated with other tumors were significantly lower than those without associated neoplasias.

CONCLUSION

In this first systematic review, we could confirm previously reported findings of a more than coincidental association between GIST and other neoplasias. The question whether there is an underlying causal association will need further investigation. Our data suggest that even GIST with a very low risk of disease progression should prompt screening for second neoplasia and subsequent frequent controls or extended staging.

Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis

INTRODUCTION

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors arising in the gastrointestinal tract. Second primary tumors (SPTs) have been reported frequently, either synchronously or during follow-up, in patients diagnosed with GISTs.

METHODS

We carried out an electronic search of PubMed, SCOPUS, Web of Science, EMBASE, and the Cochrane Library seeking articles investigating the incidence of SPTs in patients with concomitant GIST. All studies were evaluated for heterogeneity before meta-analysis and for publication bias. Pooled incidence rate was estimated using fixed- and random-effects models. Subsite of SPTs was also investigated.

RESULTS

A total of 32 studies met the inclusion criteria, for a total of 19,627 patients with a diagnosis of GIST. The pooled prevalence of SPTs was 20%, with 14% and 3% being synchronous and metachronous tumors, respectively. We found a risk for several specific cancer sites, in particular gastrointestinal (5%) and genitourinary tract cancers (3%). The most frequently associated malignancies were: colorectal (17%), prostate (14%), gastric (9%), esophageal (5.5%), lung (5.4%), hepato-biliopancreatic (4.7%), breast (4.6%), lymphoma (4.4%), kidney (4.35%), and sarcomas (3.3%). Regression analyses revealed a significant positive association for all SPTs with follow-up and Miettinen risk.

CONCLUSIONS

Our results indicate that 20% of patients with GIST experienced a SPT, primarily synchronously with a diagnosis of GIST. In particular, we observed an excess of incident gastrointestinal tumors. These findings have important implications for both pathologists, who should perform extensive molecular analysis of surgical non-GIST specimens in resected patients, and for oncologists, who should continue to follow up GIST patients.

Oesophageal GIST-A rare breed case report and review of the literature

•

We present a case of oesophageal gastrointestinal stromal tumour (GIST).

•

GISTs in the oesophagus are rare (5%) and their management is surrounded by debate.

•

Surgical therapy should aim for complete resection.

•

Preoperative biopsies are best to be avoided as they might propagate seeding.

Introduction

Gastrointestinal stromal tumours (GIST) account for only one percent of all gastrointestinal malignancies.

Presentation of case

A 53 year old lady presented to the gastroenterology clinic with iron deficiency anaemia. Oesophagogastroduodenoscopy (OGD) and computed tomography (CT) demonstrated a non-obstructing 7 cm submucosal oesophageal lesion. An oesophagectomy was performed and subsequent histology sections showed a well-circumscribed spindle cell tumour without any cellular atypia. Immunohistochemistry on the tumour was negative for S100 and positive for smooth muscle actin and desmin. C-kit (CD117) showed focal positivity in some of the tumour cells and the overall features were of a gastro-intestinal stromal tumour (GIST).

The patient has been fully compliant with the follow-up arrangements and is disease-free six years after her original operation.

Discussion

GISTs are mesenchymal tumours of the gastrointestinal (GI) tract that express the KIT protein. The incidence rate for GIST is 15 cases to one million in the USA.

GISTs in the oesophagus are rare (5%) and their management is surrounded by some debate.

Once the diagnosis has been secured the patient should be evaluated for suitability for surgical resection.

Optimal surgical therapy should aim to achieve complete resection, if possible, without injury to the pseudocapsule surrounding the tumour. Meticulous atraumatic surgical technique is necessary and preoperative biopsies are best to be avoided as they might propagate seeding.

Conclusions

Oesophagectomy with clear resection margins should be the preferred method for surgical treatment combined with the use of novel TKI strategies.

Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery

BACKGROUND

The aim of this study was to assess the role of neoadjuvant imatinib in redefining treatment for gastrointestinal stromal tumors (GISTs).

METHODS

A total of 76 patients were reviewed. Among them, 29 patients who were administered neoadjuvant imatinib for borderline resectable and locally advanced GISTs followed by surgery were analyzed. Adjuvant imatinib was administered based on risk stratification.

RESULTS

The median age of the neoadjuvant imatinib group was 51 years. The median duration of neoadjuvant imatinib administration was 8.5 months. The response rate with neoadjuvant imatinib was 79.3%. Five patients, initially considered to have locally unresectable lesions, ultimately underwent resection (three R0, two R2). Another three patients, who had M1 disease, underwent R2 resection (due to the presence of metastasis) with complete resection of the primary lesion. In 19 patients, who would have originally required extensive surgery, underwent conservative surgery (R0). In two patients, neoadjuvant imatinib did not influence the final procedure. The postoperative complication rate was 13.8%, and there were no postoperative deaths. There was one locoregional recurrence and two cases of distant metastasis. The 1-, 2-, and 3-year overall survivals were each 100%.

CONCLUSIONS

Neoadjuvant imatinib for locally advanced GISTs is a safe concept for downsizing, improving resectability, and aiding organ-preserving surgery. It also improves the chance of long-term survival. Surgery, however, remains the cornerstone of curative treatment of GISTs even after neoadjuvant imatinib.

Gender and ploidy in cancer survival

Background

Females carry a better prognosis than men for many cancer types. We hypothesized that chromosomal changes, in particular numerical alterations of the sex chromosomes or the presence of near-triploidy may contribute to these gender differences.

Methods

To characterize the influence of gender a literature search was performed for survival data of 27 tumor types. All entities were categorized by the strength of evidence for differences in survival between females and males. To test our hypothesis the Mitelman database of chromosomal alterations was evaluated for the major tumor types occurring in both women and men. Numerical gonosome alterations were documented and mean chromosome numbers were converted into histograms to provide insight into the ploidy level of 37 cancer types.

Results

In general, a survival advantage of women could be shown for most, but not all cancer types. In addition, 36.859 karyograms were analyzed. Numerical gonosome alterations were more frequent in males than females indicating a potential link with gender differences in survival. Neartriploidy was a common phenomenon in many cancer types suggesting that it represents a metastable condition of the cancer genome. It was not related to gender differences in survival. However, the extent of triploidy and aneuploidy was associated with poor prognosis in carcinomas. There was no single case in the Mitelman database with normal chromosome number (n = 46) that did not carry at least one structural or numerical aberration.

Conclusions

Our study highlights the importance of chromosomal changes in tumor formation and progression. In addition, it suggests potential associations with gender specific differences in survival.

Electronic supplementary material

The online version of this article (doi:10.1007/s13402-011-0013-0) contains supplementary material, which is available to authorized users.

[Controversies in the surgical treatment of primary gastrointestinal stromal tumours (GIST)]

It is estimated that 50% of GIST are located at the time of their diagnosis. A complete surgical resection can be performed in up to 95% of these cases, making this the most important prognostic factor. This surgery must fulfil a series of technical requirements so as to be really effective, as it has to be R0, with no tumour rupture, with preservation of the pseudo-capsule, etc. Although the majority of GIST are gastric, their location in other anatomical areas, such as the oesophagus, duodenum or rectum, require the surgeon to use more complex techniques. Laparoscopy is increasingly used; however, we must avoid its use, due to there being few experienced groups or if there are large tumours. The use of neoadjuvant therapy has revived great interest by allowing to resection tumours that were once non-resectable or in very compromised anatomical locations, with less aggressive surgery. The use of pre-surgical biopsy is not exempt from serious risks, thus it should only be used for establishing a neoadjuvant treatment or if there are diagnostic doubts with other diseases in high risk patients.

A rare cause of severe dyspareunia: a case report and literature review

Gastrointestinal stromal tumors (GISTs) of the rectum are rare, and their clinical manifestations are variable. We report the case of a 23-year-old woman who was referred complaining of dyspareunia during coitus. We performed digital vaginal and rectal investigations, ultrasound, colonoscopy, and computed tomography. These examinations confirmed the presence of a lesion measuring about 6 × 5 × 5 cm in size attached to the posterolateral left rectum wall. We performed a circumanal excision, then arrived at the mass between the muscles of the pelvic floor. Pathological studies indicated that the tumor was a high-grade GIST, and was clear at the surgical margins. On follow-up, a GIST was found at the gastric fundus via an endoscopic biopsy. Imatinib treatment was initiated because the patient refused a second operation. The gastric lesion disappeared 6 months after imatinib treatment. Dyspareunia disappeared 1 month after operation.

Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study

OBJECTIVE

The aim of this study is to evaluate the clinical significance of performing (18)F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) on patients with gastrointestinal stromal tumors (GISTs).

METHODS

The patient samples for this study were provided by seven PET institutions in Japan. Forty-one patients with pathologically proved GISTs, 24 men and 17 women (mean age 60.3 years, range 26-81 years) were enrolled in this study. Final diagnosis was based on the follow-up imaging at least 3 months after the PET scan or histopathological examinations.

RESULTS

There were eight preoperative cases and 33 follow-up cases in our series. Preoperative cases showed that the sites of primary tumor were the stomach (5 cases, 62.5%), and small intestine (3 cases, 37.5%). One stomach lesion and one small intestine lesion showed negative findings. In follow-up cases, there were 18 PET-negative cases. Among them, two cases were considered as false negative by follow-up imaging. On the other hand, 15 cases showed positive findings at 23 lesions. Most PET-positive cases were considered as true positive except for one false-positive case, who later received surgery and was diagnosed as leiomyoma histopathologically. In 14 cases, PET findings were considered to provide additional information to conventional imaging. In eight cases among them, PET findings were considered to have influenced the decision-making of therapeutic plans.

CONCLUSION

Our data suggest that FDG PET has an incremental value over conventional imaging for the diagnostic and therapeutic management of patients with GISTs in Japan as reported worldwide, and supports its introduction as a routine diagnostic tool for patients with GISTs.

Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature

PURPOSE

Data on the clinicopathological and biological profiles of gastrointestinal stromal tumours (GISTs) at higher risk for nodal metastasis are lacking.

MATERIALS AND METHODS

We reviewed our own case material and the relevant English literature.

RESULTS

Regional node metastasis was detected in two of 210 GISTs in our case material (1%) corresponding to 6% of 33 patients with nodal dissection (mean, 11 nodes) and 25% of those < or = 40 years of age. The two patients had a mean age of 32 years, contrasting with a mean age of 65 years for the whole cohort. One of them had incomplete Carney triad with pulmonary chondromas. The literature disclosed a comparable frequency of lymphatic spread among paediatric patients and young adults (approximately 20%), irrespective of the features of the Carney triad. Although a wider age range was reported in isolated reports, a majority (66%) of patients with lymph node metastasis were women < or = 40 years with gastric epithelioid/mixed type ulcerated endoluminal GIST presenting with GI bleeding.

CONCLUSION

Contrasting GISTs in elderly patients, lymphatic spread represents a common route of initial spread in patients < or = 40 with gastric GISTs, suggesting the need for node sampling in this particular subset of GIST patients. The prognostic significance of nodal metastasis in GIST patients remains to be further clarified.